The list is a menu. The clock is the pharmacology.
Performance catalogs are organized the way a person shops. Energy. Recovery. A top five. Under each heading the names arrive with a time of day attached, as if the hour were part of the molecule. It is not. A time of day is a claim about pharmacokinetics: how fast the concentration rises, how fast it falls, and whether the next dose arrives before the last one is gone.
That claim is checkable, and checking it is how a stack comes apart. Three questions cover almost every list. Has a human half-life been measured? Does that half-life, set against the interval, make a pulse or a plateau? Do the names hit one receptor or two? The evidence rung is the fourth question, and it does not move because the calendar looks tidy.
One name, two clocks
CJC-1295 is printed as if it were one compound. The short GHRH fragment — the form sold as “no DAC,” sometimes as mod GRF 1-29 — is built to be gone. Native GHRH itself lasts minutes in plasma; the fragment was made so a person could ask the pituitary for a pulse and then get out of the way. The other form wears a drug-affinity complex that sticks the peptide to albumin. In the human study that measured it, the terminal half-life was on the order of six to eight days, and IGF-1 was still up long after the injection (Teichman et al., JCEM, 2006).
The long form does not delete the pulse. A second paper, in the same journal the same year, sampled growth hormone often enough to show that bursts continued while the trough and the mean sat higher (Ionescu & Frohman, JCEM, 2006). What the albumin hitch changes is the silence between bursts. A secretagogue was supposed to leave that silence intact — that is the whole argument against injecting growth hormone itself, which replaces the rhythm with a plateau. Stretch the half-life across a week and the axis never quite returns to the quiet the sales page is promising. Two ways to ask for growth is the receptor story. The clock is why the receptor story can be undone by a suffix on the vial.
Asking for growth hormone is not one exposure. The half-life is the exposure.
- GHRH fragment (no DAC)MinutesA pulse, then silence
- CJC-1295 with DACAbout 6–8 daysPulses continue; the trough stays up
- Injected growth hormoneThe dose sets a levelA plateau in place of the rhythm
“CJC-1295” without the words “with DAC” or “without DAC” is not a specification. One clears in minutes. The other is still present days later. A stack that uses the bare name has not chosen a clock.
Two names on one button
The muscle list that shows up everywhere is CJC-1295, ipamorelin, and tesamorelin. Counted as products, that is three. Counted as signals, it is two.
Tesamorelin and CJC-1295 are both agonists at the GHRH receptor — the accelerator the hypothalamus already uses. Ipamorelin is an agonist at a different receptor, GHS-R1a, the one ghrelin uses. Giving a GHRH-receptor agonist together with a ghrelin-receptor agonist releases more growth hormone than either alone; that synergy was shown decades ago and it is the one part of the folklore that is actually a result (Bowers et al., Endocrinology, 1991). Putting tesamorelin on top of CJC-1295 does not open a third path. It presses the first button again. The only GHRH analog in that trio with an approved outcome — visceral fat, in HIV lipodystrophy — is tesamorelin, and that label does not transfer to the other two names because they share a receptor.
The same arithmetic catches the opposite error, the one that treats a weekly incretin as if it lived on the secretagogue’s clock. Semaglutide is engineered to a half-life of about a week; late in that week the level is still about half of what it was the day after the injection, which is the point of the week is not flat. A short GHRH fragment dosed at night is gone by morning. Drawing both on one twelve-week bar, as a “recomp stack,” hides two exposures that barely share an hour. How albumin binding and protease resistance buy that week is half-life engineering. The calculator will draw the curve once you have a real half-life to give it.
A clock you are not allowed to invent
Recovery lists fail the first question, which makes the other two moot. BPC-157, TB-500, and the copper peptide GHK-Cu are grouped because they are sold for the same wish — tissue that heals faster — and then assigned mornings, as if the hour were known. A morning is a statement that the concentration peaks then and matters then. For BPC-157 there is no published human half-life to be early or late relative to. The human record is uncontrolled clinic series; the randomized trial that could speak to benefit has not reported. That audit is the trial that hasn’t reported.
This is the move the long ebooks make, and it is worth naming because it sounds like caution. They tell you to journal energy, to take the repair peptide in the morning and the growth peptide at bedtime, to cycle so you do not build tolerance. The journal is fine. The schedule is a story about concentration over time, and a story about concentration requires a measurement. Where the measurement exists — tesamorelin’s daily GHRH pulse, semaglutide’s week, CJC-1295’s albumin-bound days — use it, and notice when two lines on the menu are the same line. Where it does not exist, the honest sentence is shorter than a protocol: the clock has not been measured, so the hour on the page is decoration.
- Ask for the half-life first. A time of day, a cycle, or a “loading week” is a claim that concentration has a shape. No published human half-life, no shape.
- Compare the half-life to the interval. Much shorter than the interval is a pulse. On the order of the interval is a level that is still there at the next dose. The long CJC-1295 raises the trough; it does not have to abolish pulses to stop being the silence it was sold as.
- Count receptors, not vials. CJC-1295 and tesamorelin are one GHRH-receptor signal. Ipamorelin is the second receptor, and that pair is the synergy. A third vial on the first receptor is not a third effect.
- Then read the rung. Synergy of GHRH plus a GHRP on growth-hormone release is a human result. A twelve-week muscle outcome for the gray-market list is not. Mechanism and a tidy calendar do not promote the rung.
Keep going
- Cycle planner — the same lists, with the clock written under each goal
- Two ways to ask for growth — GHRH versus the ghrelin receptor
- Half-life engineering — how a minutes-long hormone is made to last a week
- The week is not flat — what a seven-day half-life feels like
- The trial that hasn't reported — BPC-157's human record
- Mechanism is not proof — the rung under any of these claims
- Half-life calculator — pulse versus plateau, once a half-life is real
- How to read a peptide dose — four kinds of milligram
Educational reference on how to read pharmacokinetic claims in peptide marketing, drawn from public literature. Not a dosing schedule, a stack, or medical advice. Half-lives are cited from the papers named above; a catalog’s morning or bedtime label is described as a claim, not endorsed. Verify the numbers against the linked sources.